Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction

Fujifilm Toyama Chemical Co. Ltd.

Division of Fujifilm Holdings Corp.
fftc.fujifilm.co.jp/en

Latest From Fujifilm Toyama Chemical Co. Ltd.

Bookmark
  • News

Asia Deal Watch: Fujifilm Affiliate Out-Licenses Antifungal Candidate To Canada’s Appili

By Ian Haydock, Joseph Haas, Vibha Ravi and Jung Won Shin

Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.

Asia Pacific Deals
Bookmark
  • Analysis

Cynata In Potential Japan Double As Fujifilm Acquires Lead Asset

By Ian Haydock

Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.

Deals Regenerative Medicine
Bookmark
  • News

Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies

By Mandy Jackson

News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.

Financing StartUps and SMEs
Bookmark
  • Analysis

Asia Deal Watch: ReVance Licenses Chinese Rights To Botox Competitor To Fosun

By Joseph Haas, Ian Haydock, Anju Ghangurde and Jung Won Shin

With Phase III data in 2,800 patients for reducing frown lines, ReVance anticipates filing RT002 for US approval in 2019. ABL licenses two bispecific antibody candidates to TRIGR, while Sun looks to expand in dermatology with Pola buyout.

Deals Asia Pacific
See All

Company Information

  • Industry
  • In Vitro Diagnostics
  • Medical Devices
    • Diagnostic Imaging Equipment & Supplies
      • Molecular Imaging
  • Pharmaceuticals
    • Radiopharmaceuticals, Contrast Agents
  • Therapeutic Areas
  • Cancer
  • Metabolic Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Toyama Chemical Co. Ltd.
  • Fujifilm RI Pharma Co. Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Asia
      • Pacific Rim
        • Japan
  • Parent & Subsidiaries
  • Fujifilm Holdings Corp.
  • Senior Management
  • Junji Okada, Pres.
  • Contact Info
  • Fujifilm Toyama Chemical Co. Ltd.
    Phone: (81) 3 5381 3889
    14-1, Kyobashi 2-Chome
    Chuo-ku
    Tokyo ,
    Japan
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By